BIOSPRING
LIVE

Serial Number

97839291

Owner

BioSpring Gesellschaft für Biotechnologie mbH

Attorney

Julie A. Katz

First Use Date

Apr 30, 2017

Filing Date

Mar 14, 2023

Add to watchlist:

No watchlists yet
View on USPTO

BIOSPRING Trademark

Serial Number: 97839291 • Registration: 7345913

BIOSPRING is a trademark filed by BioSpring Gesellschaft für Biotechnologie mbH on March 14, 2023. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

BioSpring Gesellschaft für Biotechnologie mbH (3 trademarks)

Alt Fechenheim 34

Entity Type: 99

Trademark Details

Filing Date

March 14, 2023

Registration Date

April 2, 2024

First Use Anywhere

April 30, 2017

First Use in Commerce

April 30, 2017

Published for Opposition

January 16, 2024

Goods & Services

biochemical contract manufacturing services; chemical synthesis services, namely, custom synthesis of chemicals for others; custom manufacture of biopharmaceuticals; custom manufacture of pharmaceuticals; custom manufacturing of oligonucleotides; custom modification of antibody; custom modification of protein; development services, namely, design and development of manufacturing processes for others in the field of oligonucleotides; manufacturing, namely, contract manufacturing in the field of oligonucleotides; processing of biopharmaceutical materials for others; processing of chemical reagents; processing of chemicals; processing of medicinal materials; processing of oligonucleotides; processing of peptides; processing of proteins; technical and scientific services, namely, providing technical information in the field of pharmaceutical manufacturing

nucleic acid reagents, agents, preparations and substances for medical purposes; nucleic acid sequences for medical and veterinary use; oligonucleotides for diagnostic purposes; oligonucleotides for medical diagnostic purposes; oligonucleotides for medical use; oligonucleotides for pharmaceutical purposes; pharmaceutical preparations against genetic diseases; pharmaceutical preparations against metabolic diseases; pharmaceutical preparations against neurological diseases; pharmaceutical preparations for the treatment of cardiovascular diseases, central and peripheral nervous system diseases, respiratory diseases, cancer, allergies, gynecological diseases, rheumatic diseases, urological diseases, gastroenterological diseases, infectious diseases, eye disease, dermatological diseases, autoimmune diseases, blood diseases, genital diseases, endocrine diseases, intestinal diseases, internal medicine diseases; pharmaceutical preparations for wound healing; reagents for medical purposes; reagents for medical use; reagents for use in medical genetic testing; reagents for use in veterinary genetic testing; tumor suppressing agents

oligonucleotides for use in the manufacture of pharmaceuticals; oligopeptides for industrial use; peptide substrates for scientific use; peptides for use in industry and science; peptides for use in research and the manufacture of reagents, diagnostic reagents for science and research use; pharmaceutical intermediates for use in the further manufacture of pharmaceuticals; phosphoproteins; proteins for use in industry and science; reagents for research purposes; reagents for scientific use; nucleic acid for diagnostic research; nucleic acid for diagnostic manufacturing

nucleic acid analysis for medical diagnostic and treatment purposes; oligonucleotide analysis for medical diagnostic and treatment purposes

scientific analysis services for the identification and physical characterization of chemical molecules; scientific and technical services, namely, scientific analysis of industrial installations; scientific and technological services, namely, applied scientific research and development services, namely, conception of development or commercial batches for third parties in the fields of pharmaceuticals and chemicals; scientific and technological services, namely, consulting and assistance in the research and development of chemicals and pharmaceuticals, including experimental and production processes and installations; scientific and technological services, namely, consulting and assistance in the research and development of pharmaceuticals; scientific development services in the field of biochemistry; scientific laboratory services; scientific research and development services for chemicals for the products of third parties, namely, the scientific and technical development of synthetic processes in the field of chemistry and biochemistry; scientific research and development services in the field of pharmaceuticals; scientific research and scientific and technical development in the field of pharmaceutical, chemical, agrochemical and industrial processes; scientific research services, namely, nucleic acid analysis; scientific research services, namely, oligonucleotide analysis; scientific services, namely, scientific analysis allowing the identification and physical characterization of chemical molecules; scientific services, namely, scientific research and industrial analysis in the field of pharmaceuticals, chemicals, and agrochemical and industrial processes; scientific study and research in the area of industrial quality; development of methods of analysis for chemical and pharmaceutical products and bio-organics; scientific study and research services in the field of industrial safety

Filing History

NOTICE OF UPDATED REGISTRATION CONFIRMATION EMAILED
Nov 26, 2024 NURC
CORRECTION UNDER SECTION 7 - PROCESSED
Oct 24, 2024 COC.
TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED
Oct 23, 2024 EROP
POST REGISTRATION ACTION MAILED - SEC. 7
Oct 23, 2024 PRAM
TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED
Oct 22, 2024 EROP
POST REGISTRATION ACTION MAILED - SEC. 7
Sep 17, 2024 PRAM
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Sep 10, 2024 APRE
TEAS SECTION 7 REQUEST RECEIVED
Apr 12, 2024 ES7R
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Apr 2, 2024 NRCC
REGISTERED-PRINCIPAL REGISTER
Apr 2, 2024 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jan 16, 2024 NPUB
PUBLISHED FOR OPPOSITION
Jan 16, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Dec 27, 2023 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Dec 14, 2023 CNSA
NOTICE OF ACCEPTANCE OF AMENDMENT TO ALLEGE USE E-MAILED
Dec 14, 2023 AAUA
EXAMINER'S AMENDMENT ENTERED
Dec 13, 2023 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Dec 13, 2023 GNEN
EXAMINERS AMENDMENT E-MAILED
Dec 13, 2023 GNEA
EXAMINERS AMENDMENT -WRITTEN
Dec 13, 2023 CNEA
USE AMENDMENT ACCEPTED
Dec 13, 2023 IUAA
ASSIGNED TO EXAMINER
Dec 11, 2023 DOCK
AMENDMENT TO USE PROCESSING COMPLETE
Aug 25, 2023 AUPC
USE AMENDMENT FILED
Aug 25, 2023 IUAF
TEAS AMENDMENT OF USE RECEIVED
Aug 24, 2023 EAAU
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Apr 4, 2023 NWOS
NEW APPLICATION ENTERED
Mar 17, 2023 NWAP